TY  - JOUR
AU  - Felip, Enriqueta
AU  - Moreno, Victor
AU  - Morgensztern, Daniel
AU  - Curigliano, Giuseppe
AU  - Rutkowski, Piotr
AU  - Trigo, José Manuel
AU  - Calvo, Aitana
AU  - Kowalski, Dariusz
AU  - Cortinovis, Diego
AU  - Plummer, Ruth
AU  - Maio, Michele
AU  - Ascierto, Paolo A
AU  - Vladimirov, Vladimir I
AU  - Cervantes, Andres
AU  - Zudaire, Enrique
AU  - Hazra, Anasuya
AU  - T'jollyn, Huybrecht
AU  - Bandyopadhyay, Nibedita
AU  - Greger, James G
AU  - Attiyeh, Edward
AU  - Xie, Hong
AU  - Calvo, Emiliano
PY  - 2022
DO  - 10.1007/s00280-022-04414-6
UR  - http://hdl.handle.net/10668/19753
T2  - Cancer chemotherapy and pharmacology
AB  - To assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of cetrelimab (JNJ-63723283), a monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor, in patients with advanced/refractory solid tumors in the phase 1/2...
LA  - en
KW  - Colorectal cancer
KW  - Melanoma
KW  - Microsatellite instability–high
KW  - Monoclonal antibody PD-1 inhibitor efficacy
KW  - Non-small-cell lung cancer
KW  - Pharmacokinetics/pharmacodynamics
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Apoptosis Regulatory Proteins
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Humans
KW  - Immune Checkpoint Inhibitors
KW  - Lung Neoplasms
KW  - Melanoma
KW  - Neoplasms
KW  - Programmed Cell Death 1 Receptor
TI  - First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
TY  - research article
VL  - 89
ER  -